Stanley Laman Group, Ltd. Catalyst Pharmaceuticals, Inc. Transaction History
Stanley Laman Group, Ltd.
- $537 Million
- Q2 2025
A detailed history of Stanley Laman Group, Ltd. transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Stanley Laman Group, Ltd. holds 144,019 shares of CPRX stock, worth $2.83 Million. This represents 0.58% of its overall portfolio holdings.
Number of Shares
144,019
Previous 144,428
0.28%
Holding current value
$2.83 Million
Previous $3.5 Million
10.77%
% of portfolio
0.58%
Previous 0.66%
Shares
2 transactions
Others Institutions Holding CPRX
# of Institutions
387Shares Held
99.8MCall Options Held
37KPut Options Held
20.5K-
Black Rock Inc. New York, NY18.7MShares$367 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.5MShares$167 Million0.0% of portfolio
-
State Street Corp Boston, MA5.53MShares$109 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.42MShares$67.2 Million2.1% of portfolio
-
Goldman Sachs Group Inc New York, NY3.14MShares$61.6 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.02B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...